GlassScriptPhysician profile
Ashley Rose Gruber
NPI 1972159697
$10,267.12
in general payments reported to CMS, 2019-2025
26 companies · $2,941 in 2025
The $2,941 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $764 · 2022: $1,647 · 2023: $2,714 · 2024: $2,200 · 2025: $2,941.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,308 · Education: $505 · Consulting Fee: $42.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,307.67 |
| Education | $505.30 |
| Consulting Fee | $42.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,090.23 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,666.58 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,429.20 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,313.18 | 2021-2025 | Fasenra, Airsupra, Tezspire |
| Novartis Pharmaceuticals Corporation | $612.96 | 2021-2025 | |
| Csl Behring | $538.19 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Optinose US, INC. | $448.45 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $379.51 | 2021-2025 | Cuvitru, Hyqvia |
| Amgen INC. | $294.99 | 2022-2025 | Tezspire, Actimmune |
| Pfizer INC. | $257.83 | 2021-2023 | |
| Kaleo, INC. | $255.11 | 2021-2024 | Auvi-Q |
| Genentech USA, INC. | $207.13 | 2021-2025 | Xolair |
| Phadia US INC. | $116.93 | 2023-2025 | Immunocap |
| Sanofi-Aventis U.S. LLC | $94.95 | 2023 | |
| Leo Pharma INC. | $91.61 | 2022-2023 | Adbry |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $91.35 | 2024-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $80.04 | 2021-2023 | |
| Blueprint Medicines Corporation | $61.14 | 2023-2025 | Ayvakit |
| Ars Pharmaceuticals Operations, INC. | $58.83 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $46.00 | 2022-2024 | Ryaltris |
| Adma Biomanufacturing LLC | $42.71 | 2023 | |
| Biocryst US Sales Co., LLC | $22.95 | 2023 | Orladeyo |
| Pharming Healthcare, INC. | $22.52 | 2025 | Ruconest |
| Hologic Sales and Service, LLC | $15.77 | 2023 | Acessa Provu System |
| Lilly USA, LLC | $15.03 | 2025 | Ebglyss |
| Ionis Pharmaceuticals, INC. | $13.93 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Gruber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.